- Home
- QRVO vs TGTX Comparison
QRVO vs TGTX Comparison
Compare QRVO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QRVO
- TGTX
- Stock Information
- Founded
- QRVO 1957
- TGTX 1993
- Country
- QRVO United States
- TGTX United States
- Employees
- QRVO N/A
- TGTX N/A
- Industry
- QRVO Semiconductors
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- QRVO Technology
- TGTX Health Care
- Exchange
- QRVO Nasdaq
- TGTX Nasdaq
- Market Cap
- QRVO 7.9B
- TGTX 4.2B
- IPO Year
- QRVO 1997
- TGTX 1995
- Fundamental
- Price
- QRVO $86.81
- TGTX $32.16
- Analyst Decision
- QRVO Hold
- TGTX Strong Buy
- Analyst Count
- QRVO 19
- TGTX 4
- Target Price
- QRVO $93.83
- TGTX $42.50
- AVG Volume (30 Days)
- QRVO 1.6M
- TGTX 2.1M
- Earning Date
- QRVO 10-28-2025
- TGTX 11-03-2025
- Dividend Yield
- QRVO N/A
- TGTX N/A
- EPS Growth
- QRVO N/A
- TGTX N/A
- EPS
- QRVO 0.85
- TGTX 0.36
- Revenue
- QRVO $3,651,078,000.00
- TGTX $454,069,000.00
- Revenue This Year
- QRVO $2.18
- TGTX $82.58
- Revenue Next Year
- QRVO $4.34
- TGTX $44.99
- P/E Ratio
- QRVO $102.49
- TGTX $89.15
- Revenue Growth
- QRVO N/A
- TGTX 30.96
- 52 Week Low
- QRVO $49.46
- TGTX $21.16
- 52 Week High
- QRVO $108.44
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- QRVO 39.85
- TGTX 57.84
- Support Level
- QRVO $85.70
- TGTX $31.34
- Resistance Level
- QRVO $93.00
- TGTX $32.57
- Average True Range (ATR)
- QRVO 2.24
- TGTX 1.13
- MACD
- QRVO -0.66
- TGTX 0.54
- Stochastic Oscillator
- QRVO 13.17
- TGTX 76.20
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.